Karyopharm Therapeutics Inc.

Form 4

August 28, 2014

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per response...

**OMB APPROVAL** 

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

Name and Address of Reporting Person * Czernik Marcin			2. Issuer Name <b>and</b> Ticker or Trading Symbol Karyopharm Therapeutics Inc. [KPTI]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) SIMOU MEN COURT 8, OI		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/26/2014	Director X 10% Owner Officer (give title below) Other (specify below)		
(Street) 6015 LARNACA, G4			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person		

(City)	(State) (Z	Zip) Table	I - Non-D	erivative S	ecuri	ties Acquire	d, Disposed of, o	r Beneficially	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit oner Dispos (Instr. 3, 4)	ed of (		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK	08/26/2014		S	20,393	D D	\$ 38.5004 (1) (2)	3,007,459	I	See Footnotes (5) (6) (7)
COMMON STOCK	08/26/2014		S	1,846	D	\$ 39.0926 (1) (3)	3,005,613	I	See Footnotes (5) (6) (7)
COMMON STOCK	08/27/2014		S	21,460	D	\$ 39.0695 (1) (4)	2,984,153	I	See Footnotes (5) (6) (7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<ol> <li>Title of</li> </ol>	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Title and	d 8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transac	tionNumber	Expiration D	ate	Amount of	f Derivative
Security	or Exercise		any	Code	of	(Month/Day	/Year)	Underlying	g Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	) Derivativ	re		Securities	(Instr. 5)
	Derivative				Securities	S		(Instr. 3 an	nd 4)
	Security				Acquired				
	·				(A) or				
					Disposed				
					of (D)				
					(Instr. 3,				
					4, and 5)				
					, ,				
								Am	ount
						Date	Expiration	or	
						Exercisable	Date	Title Nun	mber
						LACICISABIC	Duic	of	
				Code	V (A) (D)			Sha	res

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					
Hadjimichael Andreas SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					
Hadjimichael Amalia SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					

# **Signatures**

Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney				
**Signature of Reporting Person	Date			
/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney				
**Signature of Reporting Person	Date			
	08/28/2014			

Reporting Owners 2

#### Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The prices reported in Column 4 are weighted average prices. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the respective ranges set forth in footnotes 2, 3 and 4 below.
- (2) The shares were sold at prices ranging from \$38.01 to \$38.95, inclusive.
- (3) The shares were sold at prices ranging from \$39.00 to \$39.19, inclusive.
- (4) The shares were sold at prices ranging from \$39.00 to \$39.18, inclusive.
  - Shares of Common Stock are owned directly by Plio Limited ("Plio"), which holds less than 10% of the outstanding Common Stock of the issuer. Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and
- investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch, the sole shareholder of Plio, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the 10,228,079 shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
- Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
- Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

#### **Remarks:**

Exhibit Index Exhibit 24.1 - Power of Attorney, dated November 5, 2013, made by Marcin Czernik and Plio Limited in favor Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3